Compare ADTN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | AUTL |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.8M | 596.2M |
| IPO Year | 1996 | 2025 |
| Metric | ADTN | AUTL |
|---|---|---|
| Price | $7.61 | $1.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $14.67 | $8.73 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,083,807,000.00 | $10,120,000.00 |
| Revenue This Year | $5.74 | $98.68 |
| Revenue Next Year | $7.88 | $28.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.46 | ★ 496.00 |
| 52 Week Low | $6.73 | $1.18 |
| 52 Week High | $19.98 | $2.58 |
| Indicator | ADTN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 38.37 |
| Support Level | $7.43 | $1.37 |
| Resistance Level | $8.73 | $1.92 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 97.22 | 13.64 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.